Articles tagged with: Thalomid
Results of a recent Spanish study suggest that elderly multiple myeloma patients who receive Velcade plus thalidomide or Velcade plus prednisone as maintenance therapy achieve deeper responses following initial therapy with Velcade-based treatment regimens.
In addition, elderly myeloma patients who receive Velcade plus thalidomide as maintenance therapy may achieve better treatment outcomes and longer survival rates than patients who receive Velcade plus prednisone as maintenance therapy.
“In our trial, VT [Velcade plus thalidomide] was slightly superior to VP [Velcade plus prednisone] in response rate and outcome, but the differences didn’t …
The results of a recent Greek study indicate that kidney impairment is highly reversible in newly diagnosed multiple myeloma patients treated with regimens containing Velcade, thalidomide, and Revlimid.
Additionally, the Greek researchers found that Velcade (bortezomib)-based treatments were associated with a shorter time to response and higher rates of restoration of kidney function than thalidomide (Thalomid)- and Revlimid (lenalidomide)-based regimens.
Based on their findings, the researchers recommend that Velcade be used as initial therapy for myeloma patients with kidney impairment.
Dr. Baldeep Wirk of the University of …
Dr. Michel Attal from the Purpan Hospital in Toulouse, France, presented a review of current maintenance therapies for multiple myeloma during the American Society of Clinical Oncology (ASCO) annual meeting last month.
The focus of Dr. Attal’s presentation was on whether there is evidence to support the use of the novel anti-myeloma agents thalidomide (Thalomid), Revlimid (lenalidomide), and Velcade (bortezomib) as maintenance therapy after initial therapy and stem cell transplantation.
Maintenance therapy refers to a prolonged, and often low-dose, form of treatment given to myeloma patients after …
The results of a recent Phase 3 study conducted throughout Europe show that treatment with a combination of Velcade, thalidomide, and dexamethasone leads to superior clinical benefits compared to treatment with thalidomide and dexamethasone alone in multiple myeloma patients who have relapsed or progressed after a stem cell transplant.
Specifically, more patients responded to the three-drug regimen. In addition, the group of patients treated with the three-drug combination responded longer and did not progress as quickly as those treated with the two-drug combination. However, the three-drug combination led to a …
The results of a recent Swedish study indicate that the development of blood clots in the veins or arteries of multiple myeloma patients negatively affects survival outcomes.
The study investigators conclude that these findings warrant further studies to determine whether blood clot prevention measures can extend the survival of myeloma patients.
“There are effective ways to prevent venous and arterial thrombosis in myeloma patients; e.g, aspirin, heparin, warfarin (Coumadin), and Pradaxa (dabigatran),” said Dr. Edward Libby of the University of Washington School of Medicine in Seattle, who was not involved …